10/8 Late treatment study
et al., NEJM, doi:10.1056/NEJMoa2007764 (Peer Reviewed)
Remdesivir for the Treatment of Covid-19 — Final Report
Remdesivir for the Treatment of Covid-19 — Final Report
RCT 1,062 hospitalized patients showing faster recovery time with treatment, median 10 days vs. 15 days for placebo, rate ratio for recovery 1.29, p<0.001.Day 29 mortality was 11.4% with remdesivir and 15.2% with placebo, hazard ratio HR 0.73 [0.52-1.03].
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Beigel et al., 10/8/2020, Randomized Controlled Trial, USA, multiple countries, North America, multiple regions, peer-reviewed, 12 authors.
risk of death, 27.0% lower, RR 0.73, p = 0.07, treatment 541, control 521.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.